Connect to other sites within the UBM Medica Network
No benefit of axillary lymph node evaluation has been shown for women with DCIS, yet this lymph node analysis is still often performed in these patients. Image © Blamb / Shutterstock.com.
Genetics May Explain Aggressive Breast Tumors in African Americans
According to the results of a genomic analysis, several genetic characteristics linked with aggressive cancer are more common in the breast tumors of African American women compared to their white counterparts.
Some Breast Cancer Patients Can Forgo Chemotherapy
Some patients with early-stage HR-positive breast cancer can be treated with hormone therapy alone, avoiding chemo without increasing their recurrence risk.
Public Awareness of Surgical Options for Breast Cancer Improves
Significantly more women are now aware of reconstructive surgery options after mastectomies for breast cancer, following coverage of Angelina Jolie’s mastectomies in 2013.
Neoadjuvant Chemo Does Not Raise Postoperative Complication Risk
A large database study found that the use of neoadjuvant chemotherapy in breast cancer patients does not raise the risk of postoperative surgical complications.
New Approaches to Women’s Health
October is Breast Cancer Awareness Month and Pregnancy and Infant Loss Awareness Month. Check here for a brief roundup of the latest women’s health news.
New Model Offers Absolute Breast Cancer Risk Assessment for Atypical Hyperplasia
A new model using only age at biopsy and number of atypia foci could improve absolute breast cancer risk estimates in women with atypical hyperplasia.
MRI Could Aid Breast Cancer Detection in Average-Risk Women
A new study found that magnetic resonance imaging (MRI) screening improved the detection of small, high-grade breast cancers in women with average risk.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
Majority of Metaplastic Breast Cancers May Be Targetable
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
Impact of ALTTO Results on Patients With HER2-Positive Breast Cancer
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.